Bulletin from the Annual General Meeting of CellaVision AB (publ) held on May 2, 2012
The CellaVision Annual General Meeting (AGM) convened earlier today in Lund, May 2, 2012, and resolved upon the following:
- Payment of dividend in the amount of SEK 0.40 per share with 7 May 2012 as record date, meaning that payment will is expected to be made on 10 May 2012
- Discharge from liability for the members of the Board of Directors and the President and CEO
- Re-election of all members of the Board and the auditor
- Resolution on remuneration for the members of the Board and the auditor
More detailed information concerning the resolutions passed at the general meeting of shareholders is available in Swedish only.
CEO Yvonne Mårtensson's address to the meeting is available via the link below.
For more information, please contact:
Lars Gatenbeck, Chairman of the Board, CellaVision AB.
Tel: +46 70 535 44 44. E-mail: lars.gatenbeck@lifemedical.se
Yvonne Mårtensson, CEO, CellaVision AB.
Tel: +46 708 33 77 82. E-mail: yvonne.martensson@cellavision.com
About CellaVision
CellaVision is an innovative, global medical technology company that develops and sells best-in-class systems for the routine analysis of blood and other body fluids. These analyses often provide critical results used in the diagnosis of a variety of illnesses such as infection and cancer. CellaVision's products reduce manual laboratory work, standardize results and support an efficient laboratory workflow. The company has leading-edge expertise in digital image analysis, artificial intelligence and automated microscopy. In 2011 sales were SEK 155 million and sales continue to increase, with a growth target of at least 15 % per year over an economic cycle. CellaVision's registered office is in Lund and the company has subsidiaries in the USA, Canada and Japan. The share is listed on the Nasdaq, OMX Stockholm, Small Cap list. Read more at www.cellavision.com.
Publication
This information is disclosed by CellaVision AB (publ) pursuant to the Securities Market Act and/or the Financial Instruments Trading Act. The information was released for public disclosure on May 2, 2012 at 18.30.